[Clinical research: course of pulmonary tuberculosis caused by polyresistant Mycobacterium tuberculosis]. 1969

G Daddi, and M Lucchesi, and P Mancini, and M Matzeu, and P Rossi

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014397 Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. Pulmonary Consumption,Pulmonary Phthisis,Pulmonary Tuberculoses,Pulmonary Tuberculosis,Tuberculoses, Pulmonary,Consumption, Pulmonary,Consumptions, Pulmonary,Phthises, Pulmonary,Phthisis, Pulmonary,Pulmonary Consumptions,Pulmonary Phthises

Related Publications

G Daddi, and M Lucchesi, and P Mancini, and M Matzeu, and P Rossi
January 1975, Problemy tuberkuleza,
G Daddi, and M Lucchesi, and P Mancini, and M Matzeu, and P Rossi
February 1968, Praxis der Pneumologie,
G Daddi, and M Lucchesi, and P Mancini, and M Matzeu, and P Rossi
February 1980, Problemy tuberkuleza,
G Daddi, and M Lucchesi, and P Mancini, and M Matzeu, and P Rossi
November 1978, Problemy tuberkuleza,
G Daddi, and M Lucchesi, and P Mancini, and M Matzeu, and P Rossi
January 2003, Problemy tuberkuleza i boleznei legkikh,
G Daddi, and M Lucchesi, and P Mancini, and M Matzeu, and P Rossi
October 2016, Chest,
G Daddi, and M Lucchesi, and P Mancini, and M Matzeu, and P Rossi
March 2015, Scientific reports,
G Daddi, and M Lucchesi, and P Mancini, and M Matzeu, and P Rossi
December 1984, Problemy tuberkuleza,
G Daddi, and M Lucchesi, and P Mancini, and M Matzeu, and P Rossi
November 2002, Emerging infectious diseases,
G Daddi, and M Lucchesi, and P Mancini, and M Matzeu, and P Rossi
January 1966, Marseille medical,
Copied contents to your clipboard!